4 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Issuer)

4 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Issuer)

8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

425 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

8-K - PIERIS PHARMACEUTICALS, INC. (0001583648) (Filer)

425 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

8-K - PIERIS PHARMACEUTICALS, INC. (0001583648) (Filer)

10-Q - PIERIS PHARMACEUTICALS, INC. (0001583648) (Filer)

EFFECT - PIERIS PHARMACEUTICALS, INC. (0001583648) (Filer)

424B3 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Filer)

425 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

S-4/A - PIERIS PHARMACEUTICALS, INC. (0001583648) (Filer)

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) currently enrolling participants at leading vascular anomaly centers across the U.S. Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs WAYNE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on develop

WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

WAYNE, PA., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced two poster presentations at the upcoming 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, taking place October 24-26, 2024, in Phoenix, AZ. The presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) as a potential targeted therapy for microcystic lymphatic malformations (microcystic LMs) and a review of the Phase 3 SELVA

FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts Ongoing Phase 3 trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations, a program with FDA's Breakthrough Therapy Designation and Fast Track Designation WAYNE, Pa., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the U.S. Food and Dr

Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapiesCombined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including approximately $78.9 million from an oversubscribed private financing with participation from a syndicate of leading healthcare-dedicated investors, which is expected to provide cash runway into the second half of 2027Anticipated cash and cash equivalents are expected to fund combined company through multiple clinical trial milestones, including pivotal P

Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the Company's existing trading symbol "PIRS".The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq Capital Market. The new CUSIP number fol

BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals. The milestone is based on dosing the first patient in a Boston Pharmaceutical-sponsored phase 1/2 study of BOS-342 (formerly PRS-342), a 4-1BB/GPC3 immuno-oncology antibody-Anticalin fusion (Mabcalin™) bispecific protein, which was discovered by Pieris and licensed to Boston Pharmaceuticals and designed to provide a potent costimulatory b

BOSTON, MA / ACCESSWIRE / July 18, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today provided a strategic update following recent events that have impacted its inhaled respiratory franchise, including AstraZeneca's discontinuation of enrollment of the Phase 2a study for elarekibep. AstraZeneca has now informed the Company of its decision to terminate the parties' R&D collaboration agreement and hand back elarekibep along with discontinuing the remaining discovery program.Pieris' management and board of directors have assesse

WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed biotechsBritish Patient Capital invests £10 million in a Series B extension bringing total raised in this round to £85.5 million Oxford, United Kingdom – 15 May 2023 – OMass Therapeutics (‘OMass', or ‘the Company'), a biotechnology company that identifies medicines against highly validated target ecosystems, today announces the appointment of Jim Geraghty as chairman of its board of directors and an additional investment of £10 million from new inve

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company's Board of Directors. Ms. Deptula-Hicks is a highly regarded financial executive with decades of experience working with and advising private and public life sciences companies. "We are excited to welcome Darlene to our Board of Directors at this important time in our company," said David de Graaf, Chief Executive Officer of Abcuro. "Darlene brings an impressive, thirty-year track record working with both publicly traded and venture-backed life

Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical OfficerShane Olwill, Ph.D., promoted to Chief Development OfficerBOSTON, MA / ACCESSWIRE / August 3, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the appointment of Tim Demuth, M.D., Ph.D. as SVP and Chief Medical Officer. Dr. Demuth will oversee all clinical, medical, safety, and regulatory aspects at the Company. Pieris additionally announced the promotion of Shane Olwill, Ph.D., formerly Head of Translational Science at Pieris, to SV

TORONTO & BOSTON--(BUSINESS WIRE)--BIONIK Laboratories Corp. (OTCQB: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced the appointment of Richard Russo, Jr. as Chief Financial Officer, effective today, November 30, 2020. Russo, Jr. will report directly to Dr. Eric Dusseux, BIONIK’s Chief Executive Officer. Russo, Jr. joins BIONIK from ICarbonX, a privately held digital health management company specializing in artificial intelligence and health data, where he held the role of Vice President of Finance and U.S. Chief Financial Officer. He o

SC 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

SC 13G/A - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

SC 13G - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

SC 13G - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

SC 13G - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

SC 13G/A - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

SC 13G/A - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

SC 13G/A - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

SC 13G/A - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

SC 13D/A - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapiesCombined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including approximately $78.9 million from an oversubscribed private financing with participation from a syndicate of leading healthcare-dedicated investors, which is expected to provide cash runway into the second half of 2027Anticipated cash and cash equivalents are expected to fund combined company through multiple clinical trial milestones, including pivotal P

COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDTEnrollment for elarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to progress with topline clinical data anticipated by mid-2024; successful safety review completed for 10 mg dose cohortPRS-220, inhaled Anticalin protein for idiopathic pulmonary fibrosis (IPF), continues in Phase 1 study with topline results expected H2 2023PRS-400, inhaled Anticalin protein for muco-obstructive respiratory disease, advances toward anticipated development candidate nomination H2 2023New preclinical data to be presented at the American Thoracic Society (ATS) 2023 International Conference in May 2023 for bot

BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host its first quarter 2023 investor call on Wednesday, May 10, 2023, at 8:00 AM EDT to discuss financial results and provide a corporate update.To access the call, participants may dial 866-682-6100 (Toll Free US & Canada) or +1 862-298-0702 (International) at least five minutes prior to the start of the call. Alternatively, a listen-only audio webcast of the call can be accessed HERE.For those unable

COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MARCH 29, 2023, AT 8:00 AM EDTContinued advancement of pipeline, including two clinical-stage inhaled respiratory programs and additional therapeutic programs for serious diseasesElarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to be enrolled by AstraZeneca; clinical data anticipated by mid-2024PRS-220, inhaled Anticalin protein for idiopathic pulmonary fibrosis (IPF), continues in Phase 1 study; topline results expected in the second half of this yearPRS-400, targeting muco-obstructive respiratory disease, advances toward development candidate nomination; additional preclinical data expected this yearBOSTON, MA /

BOSTON, MA / ACCESSWIRE / March 24, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS),a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host its year-end 2022 investor call on Wednesday, March 29, 2023 at 8:00 AM EDT to discuss financial results and provide a corporate update.To access the call, participants may dial 877-407-8920 (Toll Free US & Canada)or +1 412-902-1010 (International) at least five minutes prior to the start of the call. Alternatively, a listen-only audio webcast of the call can be accessed here.For those unable to

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2, 2022 AT 8:00 AM EDTElarekibep (PRS-060/AZD1402) phase 2a study for asthma enrollment continuesFirst subject dosed in PRS-220 phase 1 study for idiopathic pulmonary fibrosis (IPF)PRS-344/S095012 phase 1 study for solid tumors in collaboration with Servier continuesIND accepted for SGN-BB228 (also known as PRS-346) phase 1 immuno-oncology study; preclinical data to be presented at SITC 2022PRS-342/BOS-342 phase 1 for solid tumors expected to begin in the next six monthsPRS-400 preclinical data for muco-obstructive diseases presented at ERSBOSTON, MA / ACCESSWIRE / November 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)

BOSTON, MA / ACCESSWIRE / October 26, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2022 investor call on Wednesday, November 2, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.To access the call, participants may dial (888) 645-4404 (Toll Free US & Canada) or (862) 298-0702 (International) at least five minutes prior to the start of the call. Alternatively, a listen-only audio webcast of the call can be accessed here.For those

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDTAdjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23Cinrebafusp alfa (PRS-343) demonstrating clinical benefit in HER2-expressing gastric cancer patients, but Company will cease enrollment to focus its resourcesFirst-in-human regulatory submission for PRS-220 achieved, with first subject dosing planned following regulatory clearanceEscalation of PRS-344/S095012 in collaboration with Servier continuesAstraZeneca extends research collaboration, focusing on two discovery-stage programs with Pieris retaining co-development and U.S. co-commercializatio

BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2022 investor call on Thursday, August 4, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.To access the call, participants may dial (800) 285-6670 (Toll Free US & Canada) or (713) 481-1320 (International) at least five minutes prior to the start of the call. Alternatively, a listen-only audio webcast of the call can be accessed here.For those unab